Bath Savings Trust Co Sells 2,669 Shares of Johnson & Johnson (NYSE:JNJ)

Bath Savings Trust Co reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 33,245 shares of the company’s stock after selling 2,669 shares during the quarter. Bath Savings Trust Co’s holdings in Johnson & Johnson were worth $5,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $32,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $33,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $36,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 0.7%

NYSE:JNJ opened at $153.44 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The business has a 50 day moving average price of $154.43 and a two-hundred day moving average price of $153.63. The company has a market cap of $369.19 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent analyst reports. Morgan Stanley upped their price target on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 16th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Wall Street Zen cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.